Revolution in cancer treatment – what is known about new vaccines

Pharmaceutical companies Merck and Moderna have reported successful trials of a personalized mRNA vaccine against melanoma, which prevents relapses in high-risk patients. The vaccine trains the immune system to precisely attack cancer cells. Trials are also being conducted against lung, kidney, pancreatic, and colon cancers.

Pharmaceutical giants Merck and Moderna have announced successful results from clinical trials of a personalized mRNA vaccine against melanoma. The drug, created individually for each patient, trains the immune system to recognize and attack only cancer cells without affecting healthy tissue. The trial involved over a thousand patients with high-risk melanoma; the vaccine helped prevent relapses and the spread of the disease. Official presentation of the drug is expected soon, and access for thousands of patients is anticipated in the first years after approval. In addition to melanoma, the companies are testing similar vaccines against non-small cell lung cancer, kidney cancer, bladder cancer, pancreatic cancer, and stomach cancer. Companies Roche and BioNTech are also conducting trials of mRNA vaccines against colon and pancreatic cancer, with initial results for colon cancer expected in 2027. The article references a CNN publication.